Redeye returns with a more in-depth take on the Q4 results. We appreciate the company’s focus on establishing OPRA at key centres but assume a slower wide adoption of the technology for the coming years, mainly owing to bottlenecks in educational and training capacity. As such, we down our sales estimates and include a small equity raise during calendar year 2026 in our DCF model, somewhat lowering our fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/